Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2025; 13(27): 108550
Published online Sep 26, 2025. doi: 10.12998/wjcc.v13.i27.108550
Published online Sep 26, 2025. doi: 10.12998/wjcc.v13.i27.108550
Euglycemic diabetic ketoacidosis associated with etogliflozin in post-pancreatitis diabetes: A case report
Jiang-Tao Chai, Xin-Hui Li, Zhao-Shun Jiang, Department of Endocrinology, 960th Hospital of PLA, Jinan 250014, Shandong Province, China
Author contributions: Chai JT contributed to the conception, research, and drafting of the work, and approved the final version to be published; Li XH contributed to the research, and drafting of the work, and approved the final version to be published; Jiang ZS contributed to the conception, drafting, and critical revision of the work, and approved the final version to be published; They agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest related to this report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhao-Shun Jiang, Academic Editor, Chief Physician, Professor, Department of Endocrinology, 960th Hospital of PLA, No. 25 Shifan Road, Tianqiao District, Jinan 250014, Shandong Province, China. jzs012@163.com
Received: April 17, 2025
Revised: May 18, 2025
Accepted: June 24, 2025
Published online: September 26, 2025
Processing time: 110 Days and 18.9 Hours
Revised: May 18, 2025
Accepted: June 24, 2025
Published online: September 26, 2025
Processing time: 110 Days and 18.9 Hours
Core Tip
Core Tip: This is a first report of etogliflozin-induced euglycemic diabetic ketoacidosis (euDKA) in post-pancreatitis diabetes, which highlights risks of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in β-cell compromised patients. Mechanistic analysis suggests that insulin replacement therapy should be prioritized over SGLT-2 inhibitors in post-pancreatitis diabetes mellitus to mitigate euDKA risk.